The human respiratory syncytial virus (HRSV) is a major cause of lower respiratory tract infection in children worldwide. Despite decades of efforts, no vaccine is available. In this work, we report mutations that are frequent in vaccine candidates and rare in wild-type genomes, taking into account all the publicly available HRSV sequence data. These mutations are different from the ones already known to attenuate the virus, and thus may contribute to the effort towards producing a live attenuated vaccine against HRSV.
Introduction
The human respiratory syncytial virus (HRSV) is a single-strand, negative-sense RNA virus belonging to family Paramyxoviridae. It has a 15-kb genome that contains ten genes (Table 1) .
HRSV infects the respiratory tract, and causes a variety of symptoms ranging from mild to fatal. It is extremely common, almost everyone being infected for the first time by age two. It is a major cause of acute lower respiratory tract infection in children worldwide, which is in turn a significant cause of child mortality, with roughly a hundred thousand children dying from HRSV-related infection in 2005. 1 HRSV is divided into two subtypes, A and B. Subtype A appears to be more frequent in infected patients. 2 Re-infections can occur at any age, but symptoms are most severe in children under one year old, the elderly, and immunocompromised patients. 3 While prophylaxis (a monoclonal antibody marketed as Palivizumab R ) and treatment (the guanosine analog Ribavirin R ) against HRSV exist, no vaccine is currently available. Palivizumab and Ribavirin are expensive (the latter is also toxic 4 ) and only recommended for high-risk patients 5 , which makes the development of a safe and effective vaccine a high priority.
In the 1960s, an early attempt at a HRSV vaccine using formalin-inactivated virus ended in failure: the vaccine did not protect against infection and in some cases actually caused enhanced disease (including fatalities). 6 Inactivated vaccines against HRSV are no longer pursued since this fiasco. Modern approaches include particulate or subunit vaccines, gene-based vaccines, and live attenuated vaccines (LAVs). The latter are considered the most effective: although they do pose some risks, especially in immunocompromised patients and children 7 , they also offer important advantages, including the fact that they do not cause enhanced disease, that they stimulate immunity both systemically and in the respiratory tract, that they can be delivered intranasally, and that they replicate in young infants even in the presence of maternal HRSV antibody. 8 LAVs exist against measles, yellow fever, polio and smallpox, among others; they were instrumental in the eradication or near-eradication of the last two. The agent of measles, measles morbilivirus, belongs to the same family as HRSV and has a similar genomic structure and replication mechanism, demonstrating that LAVs are feasible within Paramyxoviridae.
Live attenuated vaccines are pathogens that are able to replicate in the patient, but are less virulent ("attenuated") than the wild type. One method for achieving attenuation involves several generations of culture in an environment different from the original host cell (for example, a different kind of cell or a lower temperature ("cold passage")). As the virus adapts to its new environment, it may become less adapted to the original one -thus losing virulence -while still being able to elicit a strong immune response from the host. Another approach involves chemical mutagenesis followed by selection for temperature-sensitive mutants.
Attenuation is thus the result of mutations in the viral genome. Mutations in different genes affecting different aspects of the viral cycle may equally lead to attenuation: for example, impairing replication and compromising virion stability both lead to attenuation in Poliovirus. 9 .
Understanding these mutations is useful for at least the following reasons: first, attenuation achieved by a smaller number of mutations has a higher risk of reversion to virulence than attenuation achieved by a larger number; second, a knowledge of the phenotypic effect of mutations enables a reverse genetics approach to LAV production, in which desired combinations of attenuating mutations are deliberately introduced into the viral genome; finally, the effect of mutations is generally not additive: some mutations may in fact even cancel one another -for example, one mutation in the L gene is known to compensate another mutation in the same gene 8 -hence the importance of studying the effects of combinations of mutations.
Attenuating mutations have been identified by Karron et al. through whole-genome sequencing of a cold-passaged strain as well as six temperature-sensitive derivatives of that strain. 8 . In this work, we followed a comparable approach, but using all publicly available HRSV sequence data: the public sequence databases contain thousands of HRSV sequences, both wild-type and attenuated, which we aligned together then scanned for positions in which the two groups have different allele frequencies. 
Classification of Vaccine Sequences by Subtype and Gene
Column 4 of table 2 shows a breakdown of vaccine sequences (or sub-sequences, in the case of sequences matching more than one gene) by subtype and gene. Column 5 shows the number of sequences in each category after filtering by length, retaining only full-length or near-full-length sequences.
Gene Phylogenies
Eevery gene except F shows a clear phylogenetic separation of the two subtypes ( Figure 1 , see supplementary data for all trees in Newick format and as graphical representations). It also shows that vaccines of either subtype do not form a single clade, but are instead spread out over the whole respective A or B subtree. Finally, each tree shows vaccine sequences arranged in a distinctive, stair-like pattern consisting of wholly unbalanced nodes, that is, nodes of which one child is a leaf and all other descendants descend from the other child, which is itself wholly unbalanced ( Figure 2 ).
Clade Representatives
The selection of one vaccine per unbalanced clade further reduced the number of vaccine sequences ( Table 2 , column 6). Pooled with the corresponding wild-type sequences, they yielded twenty sets of sequences, one each per (gene, subtype) pair, consisting only of full-length or nearly full-length sequences, and with a minimal number of close relatives among the vaccines. Table 4 shows all vaccine-linked, non-silent mutations for which the Fisher exact test's p-value is not greater than the significance threshold α = 0.01, after applying the Bonferroni correction for 6573 simultaneous comparisons (one per non-conserved position in the genome) -this results in a corrected α = 1.52 × 10 −6 . No position matching these criteria was found in subtype B. Column 12 of the table shows the effect size as the odds ratio of a vaccine vs. a wild-type sequence having the minor allele at a given position, flanked by the lower bound of the 95% confidence interval around the ratio (column 12) and the upper bound (column 13). None of the intervals includes the value 1, indeed the minimal lower bound is 12.
Vaccine-linked Mutations

Number of mutations in vaccine versus wild-type sequences
Vaccine sequences were heavily mutated at the vaccine-linked positions (Table 3) . Indeed, in the attachment glycoprotein and nucleoprotein, every vaccine sequence differs from the wild type at all positions, and even in the fusion glycoprotein and polymerase the average number of mutated positions per sequence (4.14 and 12.33) are close to the maxima (5 and 13), respectively. The phylogeny of gene L. Subtype A is in blue (wild-type) and cyan (vaccines); subtype B in red (wild-type) and magenta (vaccines). The tree was re-rooted on the bovine RSV ortholog, the purely vaccine clades condensed into single leaves, and the resulting tree rendered as SVG using the Newick Utilities. 10 
Non-attenuated Vaccines
Vaccine sequences not explicitly annotated as "attenuated" may result from a process other than attenuation and thus not harbour attenuation-linked mutations. This will result in an underestimation of the frequency of these mutations among attenuated sequences, resulting in a higher false negative rate.
Independence of Mutation events
The phylogenetic trees constructed for each gene of both HRSV subtypes clearly show extremely unbalanced nodes, that is, nodes of which one child is a single leaf, and the other child has several descendants. That other child node is frequently itself extremely unbalanced, resulting in strongly or even wholly unbalanced clades (Figure 2 ). Such clade topologies are expected to arise when a sample is taken from a culture to start a new culture, and the process is iteratively repeated: all cultures but the first are more closely related to each other than any of them is to the first culture, and the same situation obtains recursively within the last-but-one cultures. The result is an extremely unbalanced phylogeny.
Any early mutation will therefore (barring reversion) be inherited by most of the members of the clade, and be found at a high frequency. However, this high frequency is not indicative of a high number of independent mutation events, but rather, of inheritance. It is therefore wrong to interpret this high frequency as a sign of positive selection. In the context of this work, the mutation would be wrongly thought of as a result of the attenuation process.
Our approach to this problem, namely the selection of a single sequence per fully unbalanced vaccine clade, makes it less likely that any similarities are due to shared ancestry. Furthermore, the fact that we select among the sequences with the maximal number of ancestors in the clade should maximize the number of mutations that we are able to detect.
Effect on Phenotype Most mutations retained by our pipeline are silent. Among the non-silent ones, the most likely to affect the phenotype are arguably those which are most rarely encountered between homologous sequences, as measured for example by the BLOSUM 11 amino acid substitution scores.
Another approach to estimating the effect of a mutation is to consider any known function of the affected protein or regions therein. Table 5 shows annotations pertaining to regions harbouring mutations, according to UniProtKB 12 . , and 523), none of which were retained by our procedure. So does NCAP_HRSVA (V267I). Since the method of attenuation (and indeed of vaccine production) is usually not known for our vaccine genomes, it is impossible to use these known mutations as positive controls, and we can only note that the mutations we identified are hitherto unknown.
Affected Subtypes Our procedure only identified mutations in vaccines derived from HRSV subtype A, but the failure to find mutations in type B is possibly due to the lower number of sequences available from that subtype, as this would lower the power of the statistical test used to identify positions with distinct allele frequency distributions between wild-type and vaccine sequences.
Limitation to Coding Regions Our procedure is limited to coding regions of the HRSV genome. Any mutation falling outside of coding regions will thus be missed, and attenuating mutations in non-coding regions have been reported (in transcription start sites, for example 13 ). However, of the six attenuating point mutations reported by Karron et al. 8 , five were in coding regions, which suggests that limiting our procedure to coding regions is unlikely to cause it to overlook all (or perhaps even most) mutations of interest.
Incompatible Mutations While the design of vaccines by reverse genetics will likely benefit from an expanded list of attenuation-linked mutation candidates, it should be borne in mind that mutations may be pairwise incompatible. 14 In summary, we identified a set of positions and corresponding alleles, in the human respiratory syncytial virus subtype A (HRSV-A), which are likely to be under selection by the process of attenuation carried out in the production of candidate live HRSV vaccines. We also found that the vaccine sequences almost never have the wild-type allele at the corresponding position. If, as seems likely, the vaccine sequences are not closely related, this means that the separate attenuation processes have independently converged on the same mutations. We found no comparable mutations in subtype B, but this can be due to small sample size rather than lack of selection pressure.
These findings adds to the current understanding of the genome-scale effects of attenuation in HRSV, and may find application in the direct engineering of live attenuated vaccines.
Methods
Overview
We aligned homologous gene sequences from vaccine candidates and wild-type viruses together (but keeping the two subtypes separate), and searched for positions with significantly different allele frequencies in the two groups. To identify positions with different allele frequencies in vaccine vs. wild-type sequences, we first had to distinguish these two categories, and to classify sequences by gene and subtype when not annotated. The detailed procedure (implemented using Python 15 (including BioPython 16 ), Bash 17 , SQLite 18 , and R 19 ) follows.
Download and Sorting of Raw Sequence Data
We downloaded all entries with key phrase Respiratory syncytial virus from GenBank 20 . There were 28,248 at the time of download -see supplementary file all.gb. This included both whole-genome and partial HRSV sequences, of both subtypes, mostly wild type but with a small minority annotated as "vaccines". Although it would be more accurate to refer to these as "vaccine candidates", this phrase is unwieldy and we will refer to these as "vaccines" in the rest of this article.
A small number of entries were not from human respiratory syncytial virus, and were discarded. We then separated wild-type from vaccine sequences based on annotation: any entry containing the string VACCINE, ATTENUAT, or PATENT in the Definition, Source, Reference Titles, or Comments fields of the GenBank entry was considered a vaccine sequence (this assumes that patented sequences are vaccines); all others were considered wild-type.
Likewise, we separated the two subtypes of wild-type viruses by annotation, using various regular expression searches for patterns such as type (A|B) in the Source, Organism, or Definition fields of the Genbank entry, as well as in its Feature Table ( for the full details, see the source code in file allRSVtoCSV.py in the supplementary data). Entries whose subtype could not be determined were discarded.
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